Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.72 USD
-0.07 (-3.91%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.72 0.00 (0.00%) 7:42 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FBIO 1.72 -0.07(-3.91%)
Will FBIO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FBIO
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
FBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
Other News for FBIO
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Avenue Therapeutics Announces Reverse Stock Split
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Fortress Biotech price target raised by $14 at H.C. Wainwright, here's why